Hatteras Venture Partners — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
GeneCentric develops ExpressCT, a fragmentomics technology that extracts gene expression measurements from circulating tumor DNA sequencing data to enable expression-based biomarkers for cancer diagnostics and precision oncology.
BiotechDigital HealthMedical DevicesDurham, US
MICHAEL MILBURN(Executive Officer, Director)CHARLES PEROU(Director)David Neil Hayes(Executive Officer, Director)Charles Perou(Director)Arnold Levine(Director)
Board seatMyla Lai-GoldmanClay Thorp· per SEC Form D
Co-investorsIAG Capital Partners
BiotechDurham, US
Heather Madsen(Ms. Madsen is a director and the CEO of the issuer.)William Wiesler(Executive Officer, Director)
Board seatHolden ThorpClay ThorpChristy Shaffer· per SEC Form D · $2.5M raise · filed Nov 2025
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2.
BiotechHealthtechDurham, US
Patrick Roberts(Executive Officer and member of the Board of Managers.)
BoardFredric N. Eshelman(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)Norman Sharpless(Member of the Board of Managers.)
Co-investorsCape Fear BioCapitalEshelman Ventures, LLCHatteras
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.